

NIH Public Access

Author Manuscript

Subst Use Misuse. Author manuscript; available in PMC 2013 September 19.

Published in final edited form as:

Subst Use Misuse. 2013 January ; 48(0): 99–105. doi:10.3109/10826084.2012.731674.

Test-retest reliability of self-report measures in a dually diagnosed sample

Jon M. Houck, Ph.D.,

Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque, NM

Mind Research Network, Albuquerque, NM

Alyssa A. Forcehimes, Ph.D.,

Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque, NM

Elisa T. Gutierrez, B.S., and

Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque, NM

Michael P. Bogenschutz, M.D.

Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM

University of New Mexico Center on Alcoholism, Substance Abuse, and Addictions University of New Mexico, Albuquerque, NM

Abstract

Many individuals diagnosed with a substance use disorder are also diagnosed with another psychiatric disorder. Little is known regarding which treatments are efficacious for these duallydiagnosed individuals (DDI). Characterizing the psychometric properties of assessments used with DDI samples is essential to efficacy studies with DDI. This study examined the internal consistency and test-retest reliability of self-report instruments in DDI. Most subscales demonstrated high test-retest reliability; one subscale demonstrated poor reliability. Internal consistency was similar to that of non-DDI samples. This exploratory study suggests that, while some instruments should be interpreted cautiously, DDI samples can be accurately assessed with self-report measures.

Keywords

Dual diagnosis; psychometrics; substance abuse; self report

Introduction

The prevalence of co-occurring mental health and substance use issues in clinical populations is so high that dual diagnosis is considered the norm rather than the exception. Individuals diagnosed with both a substance use disorder (SUD) and another psychiatric disorder account for 41%-65% of substance abusers (USDHHS, 1999). While these rates

Declaration of Interest

The authors report no conflicts of interest

Corresponding author: Jon M. Houck, Ph.D., 2650 Yale Blvd. SE, Rm. 231, Albuquerque, NM 87106, Phone: (505) 730-9760, Fax: (505) 925-2301, jhouck@unm.edu.

may seem high, they are consistent across a range of studies (Cantor-Graae, Nordström, & McNeil, 2001; Margolese, Malchy, Negrete, Tempier, & Gill, 2004; Regier, et al., 1990; Swartz, et al., 2006). Over 40% of those seeking treatment for an alcohol use disorder also report a mood disorder, while 33% report an anxiety disorder (Grant, et al., 2004). Both epidemiological surveys and studies of clinical populations have consistently documented these high comorbidity rates.

When substance use and mental illness are comorbid, each is exacerbated (Swann, 2010). Comorbid disorders are more severe and have a greater effect on patients' quality of life than does a single diagnosis (Burns & Teesson, 2002; Kessler, 1995). Among those with severe mental illness (SMI), substance use problems are associated with more frequent relapses and more psychosocial consequences (McLellan, Luborsky, Woody, O'Brien, & Druley, 1983). The presence of a comorbid substance use disorder may also affect symptomatology in patients with a severe mental illness (e.g., Talamo, et al., 2006). Conversely, treatment for substance use can improve the course of the comorbid mental illness (Smelson, et al., 2008).

While comorbidity is a dominant clinical reality for most treatment settings, traditional approaches have generally isolated treatment for substance abuse from treatment for other mental illnesses. Integrated treatment models that combine mental health and substance use interventions are needed to address the needs specific to those with co-occurring disorders (Drake, et al., 2001; Horsfall, Cleary, Hunt, & Walter, 2009; Weiss, et al., 2007). However, instruments examined in non-mentally ill SUD patients may not display similar psychometric characteristics in dually diagnosed individuals (DDI). Few studies assessing the reliability and validity of standard self-report instruments have been conducted in this population, and the available studies raise serious concerns. For example, the Addiction Severity Instrument ASI: (McLellan, et al., 1992) is a psychometrically-sound scale used in SUD treatment settings to assess functionality. While some evidence exists supporting the validity of ASI in DDI, most studies indicate mixed reliability and validity, impeding research using this instrument (Carey, Cocco, & Correia, 1997; Hodgins & el-Guebaly, 1992; Zanis, McLellan, & Corse, 1997). Despite this, the instrument is widely used in DDI populations (Appleby, Dyson, Altman, & Luchins, 1997; Weiss, et al., 2007).

When assessment tools designed for a specific population are adapted for another group, it is important to evaluate the relevance of their content. Scales should be reviewed to assure appropriateness and reduce ambiguity. Many instruments show inconsistent temporal stability across populations. For example, while the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) has adequate test-retest reliability in mentally ill populations, it has shown poor test-retest reliability (r=.49) in a dually-diagnosed sample (Lykke, Hesse, Austin, & Oestrich, 2008). No published reliability data from dually-diagnosed populations are available for the instruments included in this paper

Current Study

Psychometric properties for many measures commonly used in DDI populations have been developed and tested in non-mentally-ill populations (e.g., Miller & Tonigan, 1996; Moyers & Miller, 1993; Tonigan, Miller, & Vick, 2000). However, to date, no psychometric data are available for many instruments with DDI populations. The present study reports the test-retest reliability and internal consistency of seven such measures. These data were collected as part of an exploratory aim in an NIH-funded clinical trial assessing the effectiveness of a twelve-step facilitation program specially adapted to meet the needs of those with co-occurring disorders. The aims of this analysis were to (1) provide the first test-retest reliability estimates for seven self-report measures in DDI, and (2) compare test-retest reliability between groups with different psychiatric diagnoses. Findings of this study will

allow for further evaluation of 12-step treatment and provide data in regard to the use of traditional measurements in DDI.

Material and methods

Participants

Participants consisted of the first 39 subjects enrolled in a randomized controlled trial of a modified twelve-step facilitation program. To meet inclusion criteria, patients must have met diagnostic criteria for either a psychotic disorder or a major mood disorder in addition to alcohol abuse or dependence. The majority of participants were male (56.4%), with a mean age of 40, ranging from 24 to 54 years of age. About half (53.8%) of the participants were Caucasian, 40.5% were Hispanic. Racioethnic data were not supplied by 2 of the participants. Two-thirds of the participants were single or divorced and two-thirds were unemployed. Frequencies of psychiatric diagnoses are provided in Table 1.

Measures

The Alcohol Abstinence Self-efficacy Scale (AASE; DiClemente, Carbonari, Montgomery, & Hughes, 1994) is a 40-item scale asks the respondent to rate their temptation to drink and the confidence they have to avoid drinking in different situations. The Stages of Change and Treatment Eagerness Scale (SOCRATES) measures the patient's motivation to change (Miller & Tonigan, 1996). The Understanding of Alcoholism Scale (UAS) assesses the patients' beliefs about alcoholism (Moyers & Miller, 1993). A 3-item subscale of the 12-Step Participation questionnaire (TSPQ) is used to quantify attendance in 12-step programs (Tonigan, Miller, & Connors, unpublished instrument). The 12-step and Double Trouble in Recovery (DTR) versions of the Twelve Step Attitudes Questionnaire for Dual Diagnosis (TSAQ-DD) were developed in order to measure patients' attitudes toward these interventions (Bogenschutz & Akin, 2000). The General Alcoholics Anonymous Tools for Recovery (GAATOR) is a 26-item scale that measures endorsement of prescribed 12-step spiritual beliefs and practices (Montgomery, Miller, & Tonigan, 1995).

Procedure

All procedures for this study were approved and overseen by the Human Research Review Committee (HRRC) of the University of New Mexico. Participants were administered a battery of seven self-report assessment instruments at baseline and at week one. The oneweek interval was chosen in order to balance the concern for change in attributes measured with that of recall of previous responses. The battery included five commonly-used scales whose psychometric properties have not been characterized in this population and two new scales developed specifically to address the attitudes of DDI towards 12-step programs.

Data analysis

Two types of test-retest reliability estimates were computed: absolute agreement, as estimated by the intraclass correlation coefficient (Shrout & Fleiss, 1979), and relative agreement, as estimated by Pearson's *r*. While high relative agreement would indicate that the rank orderings of scores were consistent across the one-week period, high absolute agreement would suggest that the scores themselves, not just their relative rankings, remained stable over time. The ICC is the focus of this analysis because it provides an unbiased estimate of reliability and excludes systematic variation across the time period (Berk, 1979).

Results

Descriptive Statistics and Internal Consistency

Means, standard deviations, and coefficient alphas for full scales as well as subscales are provided in Table 2. The majority of the subscale coefficients fell in the recommended range of above .70 (Nunnally & Bernstein, 1994), demonstrating sufficient intercorrelation among items.

Test-Retest Reliability

Intraclass correlation coefficients (ICCs) and Pearson correlation coefficients are provided in Table 3. Most ICCs were in the good (.60–.74) to excellent (.75–1.00) range (Cicchetti & Sparrow, 1981), demonstrating high reliability. One subscale, Understanding Alcoholism Scale- Moral/Spiritual, demonstrated poor (< .40) reliability. It is worth noting that the UAS was developed for use with substance abuse clinicians, not clients, and that the Moral/ Spiritual subscale has not yet been validated in any population.

Differences Associated with Diagnosis

Differences were observed between patients with depressive disorder and other disorders. ICCs and effect sizes (q; Cohen, 1988) for between-group differences can be found in Table 4. Although neither a depressive disorder nor a psychotic disorder was related to poor test-retest reliability and/or consistency in all scales, each diagnostic group showed low stability over time on at least one scale. In general, the scores in the depressive group were less reliable than were scores in the other group. No scale showed poor reliability in both diagnostic categories. It may be the case that distinct deficits observed in temporal stability are related to diagnosis. However, the effect sizes for the majority (13 of 18) of the scales and subscales were small (10–.29).

One scale for which diagnosis had a large (> .50) effect size was the DTR version of the TSAQ-DD. Stability for the Positive Attitude and Illness-Related Problems subscales was considerably lower in the depressed group than in the psychotic group. However, the TSAQ for Twelve Step Programs showed excellent reliability in this same group. The TSAQ for Twelve Step and for DTR are nearly identical; the only difference involves to which mutual-help program the participants refer in their responses. Both of these scales showed excellent reliability in the psychotic group. Given the high reliability of the Twelve Step version of this scale in both groups, the poor reliability of the TSAQ-DD for DTR may reflect more limited engagement in or knowledge of Double Trouble in Recovery among the depressive participants.

Discussion

The use of self-report measures has traditionally been a cause for concern in clinical and research settings, and even more so in individuals with co-occurring substance use and psychiatric disorders. The results presented here should alleviate some of this concern. Based on the findings of this study, self-report instrumentation in DDI samples can be quite reliable. Deficits related to a dual diagnosis do not appear to significantly impair the participant's ability to fully and reliably engage in research and treatment settings. In sum, the majority of the self-report instruments evaluated in this study are stable in DDI populations. This exploratory study suggests that the participation of DDI in research studies can be accurately quantified with self-report measures.

These findings should be interpreted with caution given the heterogeneity of the sample and the small sample size, which limit power and the generalizability of these results. Definitive

conclusions are not possible without a larger sample. In addition, future studies should characterize the psychometric properties of scales with specific clinical populations and conditions of interest, as specific scales may perform differently in some psychiatric populations.

Acknowledgments

Funding for this study was provided by NIAAA grants R01 AA015419 (NCT00583440) and K24 AA016555. We would like to thank Dr. J. Scott Tonigan for his helpful advice on the statistical analysis of this manuscript.

References

- Appleby L, Dyson V, Altman E, Luchins DJ. Assessing substance use in multiproblem patients: reliability and validity of the Addiction Severity Index in a mental hospital population. The Journal of Nervous and Mental Disease. 1997; 185:159–165. [PubMed: 9091597]
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Archives of General Psychiatry. 1961; 4:561–571. [PubMed: 13688369]
- Berk RA. Generalizability of behavioral observations: a clarification of interobserver agreement and interobserver reliability. American Journal of Mental Deficiency. 1979; 83:460–472. [PubMed: 426006]
- Bogenschutz MP, Akin SJ. 12-Step Participation and Attitudes Toward 12-Step Meetings in Dual Diagnosis Patients. Alcoholism Treatment Quarterly. 2000; 18:31-31.
- Burns L, Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders: Findings from the Australian National Survey of Mental Health and Well Being. Drug and Alcohol Dependence. 2002; 68:299–307. [PubMed: 12393224]
- Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia Research. 2001; 48:69–82. [PubMed: 11278155]
- Carey KB, Cocco KM, Correia CJ. Reliability and validity of the Addiction Severity Index among outpatients with severe mental illness. Psychological Assessment. 1997; 9:422–428.
- Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. American Journal of Mental Deficiency. 1981; 86:127–137. [PubMed: 7315877]
- Cohen, J. Statistical Power Analysis for the Behavioral Sciences. Mahwah, NJ: Lawrence Erlbaum Associates; 1988.
- DiClemente CC, Carbonari JP, Montgomery RP, Hughes SO. The Alcohol Abstinence Self-Efficacy scale. Journal of Studies on Alcohol. 1994; 55:141–148. [PubMed: 8189734]
- Drake RE, Essock SM, Shaner A, Carey KB, Minkoff K, Kola L, Lynde D, Osher FC, Clark RE, Rickards L. Implementing Dual Diagnosis Services for Clients With Severe Mental Illness. Psychiatric Services. 2001; 52:469–476. [PubMed: 11274491]
- Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and Co-occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004; 61:807–816. [PubMed: 15289279]
- Hodgins DC, el-Guebaly N. More data on the Addiction Severity Index. Reliability and validity with the mentally ill substance abuser. The Journal of Nervous and Mental Disease. 1992; 180:197– 201. [PubMed: 1588339]
- Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial Treatments for People with Co-occurring Severe Mental Illnesses and Substance Use Disorders (Dual Diagnosis): A Review of Empirical Evidence. Harvard Review of Psychiatry. 2009; 17:24–34. [PubMed: 19205964]
- Kessler RC. The National Comorbidity Survey: Preliminary results and future directions. International Journal of Methods in Psychiatric Research. 1995; 5:139–151.
- Lykke JR, Hesse M, Austin SF, Oestrich I. Validity of the BPRS, the BDI and the BAI in dual diagnosis patients. Addictive Behaviors. 2008; 33:292–300. [PubMed: 17976924]

- Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research. 2004; 67:157–166. [PubMed: 14984874]
- McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment. 1992; 9:199–213. [PubMed: 1334156]
- McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA. Predicting Response to Alcohol and Drug Abuse Treatments: Role of Psychiatric Severity. Archives of General Psychiatry. 1983; 40:620–625. [PubMed: 6847331]
- Miller WR, Tonigan JS. Assessing Drinkers' Motivation for Change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychology of Addictive Behaviors. 1996; 10:81– 89.
- Montgomery HA, Miller WR, Tonigan JS. Does alcoholics anonymous involvement predict treatment outcome? Journal of Substance Abuse Treatment. 1995; 12:241–246. [PubMed: 8830150]
- Moyers TB, Miller WR. Therapists' Conceptualizations of Alcoholism: Measurement and Implications for Treatment Decisions. Psychology of Addictive Behaviors. 1993; 7:238–245.
- Nunnally, J.; Bernstein, I. Psychometric Theory. New York: McGraw-Hill; 1994.
- Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of Mental Disorders With Alcohol and Other Drug Abuse: Results From the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association. 1990; 264:2511–2518. [PubMed: 2232018]
- Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin. 1979; 86:420–428. [PubMed: 18839484]
- Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008
- Swann AC. The strong relationship between bipolar and substance-use disorder. Annals of the New York Academy of Sciences. 2010; 1187:276–293. [PubMed: 20201858]
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Cañive JM, Lieberman JA. Substance Use and Psychosocial Functioning in Schizophrenia Among New Enrollees in the NIMH CATIE Study. Psychiatr Serv. 2006; 57:1110– 1116. [PubMed: 16870961]
- Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophrenia Research. 2006; 86:251–255. [PubMed: 16750347]
- Tonigan JS, Miller WR, Connors GJ. Twelve Step Participation Questionnaire. (unpublished instrument). Available from http://casaa.unm.edu/inst.html.
- Tonigan JS, Miller WR, Vick DH. Psychometrics on the General Alcoholics Anonymous Tools of Recovery (GAATOR 2.1). Alcoholism: Clinical and Experimental Research. 2000; 24
- USDHHS. Mental Health: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
- Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau HR, Hennen JA. A Randomized Trial of Integrated Group Therapy Versus Group Drug Counseling for Patients With Bipolar Disorder and Substance Dependence. Am J Psychiatry. 2007; 164:100–107. [PubMed: 17202550]
- Zanis DA, McLellan AT, Corse S. Is the Addiction Severity Index a Reliable and Valid Assessment Instrument Among Clients with Severe and Persistent Mental Illness and Substance Abuse Disorders? Community Mental Health Journal. 1997; 33:213–227. [PubMed: 9211041]

Frequencies of Psychiatric Diagnosis.

Diagnosis	Frequency	Percent
Major Depressive Disorder	20	51.3
Depressive Disorder NOS	1	2.6
Bipolar I Disorder	4	10.3
Other Bipolar Disorder	4	10.3
Schizophrenia	6	15.4
Schizoaffective Disorder	2	5.1
Delusional Disorder	1	2.6
Psychotic Disorder NOS	1	2.6

Descriptive Statistics and Internal Consistencies for Baseline and One-week Assessments

a. 1	Baseline		One-Week	
Scale	Mean (SD)	Cronbach's	Mean (SD)	Cronbach's
TSPQ	4.33 (9.77)	0.392	0.21 (4.05)	0.329
TSAQ-DD (Twelve Step)				
Positive Attitude	0.61 (0.30)	0.834	0.61 (0.31)	0.861
Illness Related Problems	0.53 (0.32)	0.741	0.54 (0.31)	0.702
TSAQ-DD (Double Trouble)				
Positive Attitude	0.75 (0.28)	0.857	0.84 (0.26)	0.922
Illness Related Problems	0.30 (0.27)	0.632	0.26 (0.26)	0.700
GAATOR Total	13.4 (7.9)	0.896	13.7 (8.8)	0.917
Higher Power	7.1 (4.7)	0.905	6.9 (4.6)	0.901
Inventory	2.8 (2.4)	0.766	2.4 (2.5)	0.777
Self-Inventory	1.2 (1.3)	0.515	1.6 (1.4)	0.455
AASE				
Temptation	48.6 (13.2)	0.870	47.7 (15.6)	0.925
Confidence	41.4 (17.2)	0.929	36.7 (16.5)	0.923
SOCRATES				
Recognition	29.4 (5.4)	0.868	29.2 (5.5)	0.863
Ambivalence	13.5 (3.5)	0.537	13.6 (4.4)	0.804
Taking Steps	32.3 (5.4)	0.823	33.3 (6.4)	0.921
UAS				
Disease Model	3.4 (0.53)	0.778	3.4 (0.60)	0.829
Psychosocial	3.6 (0.53)	0.639	3.6 (0.61)	0.771
Heterogeneity	3.0 (0.47)	0.072	2.9 (0.51)	0.082
Moral/Spiritual	3.0 (0.73)	0.746	3.1 (0.76)	0.765

Note. AASE: Alcohol Abstinence Self-efficacy Scale ; GAATOR: General Alcoholics Anonymous Tools for Recovery; SOCRATES: Stages of Change and Treatment Eagerness Scale; TSPQ: 12-Step Participation questionnaire; TSAQ-DD: Twelve Step Attitudes Questionnaire for Dual Diagnosis; UAS: Understanding of Alcoholism Scale

.

Test-Retest Estimates for Twelve-Step Instruments

Scale	ICC	95%	6 CI	Pearson r
		Lower Bound	Upper Bound	
TSPQ	0.686	0.406	0.850	0.729 **
TSAQ-DD (Twelve Step)				
Positive Attitude	0.870	0.732	0.939	0.867**
Illness Related Problems	0.877	0.769	0.938	0.877 **
TSAQ-DD (Double Trouble)				
Positive Attitude	0.533	-0.047	0.841	0.519
Illness Related Problems	0.652	0.197	0.886	0.652*
GAATOR Total	0.766	0.585	0.874	0.764 **
Higher Power	0.740	0.549	0.858	0.743 **
Inventory	0.551	0.271	0.736	0.551 **
Self-Inventory	0.744	0.552	0.861	0.756***
AASE				
Temptation	0.744	0.540	0.865	0.756***
Confidence	0.436	0.118	0.675	0.445*
SOCRATES				
Recognition	0.839	0.712	0.913	0.836**
Ambivalence	0.501	0.217	0.707	0.507**
Taking Steps	0.482	0.199	0.692	0.489 **
UAS				
Disease Model	0.624	0.385	0.785	0.625 **
Psychosocial	0.744	0.556	0.859	0.741 **
Heterogeneity	0.652	0.427	0.802	0.661 **
Moral/Spiritual	0.370	0.062	0.615	0.369*

p < .05 (2-tailed)

** p < 0.01 (2-tailed);

 $\stackrel{\wedge}{=}$ Excellent reliability

= Good reliability

= Fair reliability

= Poor Reliability

Note. AASE: Alcohol Abstinence Self-efficacy Scale; GAATOR: General Alcoholics Anonymous Tools for Recovery; SOCRATES: Stages of Change and Treatment Eagerness Scale; TSPQ: 12-Step Participation questionnaire; TSAQ-DD: Twelve Step Attitudes Questionnaire for Dual Diagnosis; UAS: Understanding of Alcoholism Scale

Test-Retest Estimates and Effect Sizes for Twelve-Step Instruments in Depressive and Other Groups

Scale	cale ICC		Effect Size	
	Depressive	Other		
TSPQ	.604*	.815 **	-0.444	
TSPQ-DD (Twelve Step)				
Positive Attitude	.859 **	.886**	-0.113	
Illness Related Problems	.876**	.891 **	-0.068	
TSPQ-DD (Double Trouble)				
Positive Attitude	.252	.869 **	-1.071	
Illness Related Problems	.359	.910***	-1.152	
GAATOR Total	.800 **	.656*	0.313	
Higher Power	.761 **	.706*	0.119	
Inventory	.470 ^	.736*	-0.432	
Self-Inventory	.667*	.773 **	-0.222	
AASE				
Temptation	.680*	.809 **	-0.295	
Confidence	.220	.633*	-0.523	
SOCRATES				
Recognition	.784 **	.909 **	-0.466	
Ambivalence	.294	.684*	-0.534	
Taking Steps	.575 ^	.355 ^^	0.284	
UAS				
Disease Model	.770 **	.540 ^	0.416	
Psychosocial	.846**	.637*	0.489	
Heterogeneity	.728*	.535 ^	0.327	
Moral/Spiritual	.608*	.179	0.525	

Note: "Other" disorders include both psychotic disorders and bipolar disorders. Effect size is q (Cohen, 1988).

** = Excellent reliability

* = Good reliability

 $\stackrel{\checkmark}{=}$ Fair reliability

= Poor reliability